On February 28, 2024, NORTHLAND's ninth batch of nationally procured drug products—Diquafosol Sodium Eye Drops (Hui Liang) ^R ) The first batch of products has been successfully shipped and is now officially available for sale. Sodium Diclofenac Eye Drops are NORTHLAND’s first product to win a centralized procurement bid as the marketing authorization holder. The company obtained the Drug Registration Certificate for this product in August 2023 and successfully won the bid in the 9th National Drug Centralized Procurement Round in November of the same year, with the selected regions being Shandong, Tianjin, Gansu, Inner Mongolia, Hainan, and Guizhou—six provinces and cities in total.

         Diquafosol sodium eye drops are a novel therapeutic agent for dry eye syndrome. Unlike traditional artificial tears, which alleviate patient discomfort primarily through lubrication, diquafosol sodium is a P2Y2 receptor agonist that promotes the secretion of mucin, aqueous humor, and lipids, thereby comprehensively enhancing tear film stability. Additionally, it exhibits corneal epithelial repair properties and can be used to treat ocular surface damage caused by dry eye. Furthermore, diquafosol sodium also intervenes in the inflammatory pathway underlying dry eye pathogenesis, inhibiting inflammatory signaling pathways and inflammatory cytokines.

         The company’s product has successfully made its debut and been smoothly delivered, marking the official entry of sodium dezocine eye drops into the commercial operation phase. The company will, with reliable quality and premium service, fully ensure the supply of nationally centralized procurement drugs. At the same time, the company will actively explore a broader ophthalmic market, providing high-quality ophthalmic medications to numerous patients suffering from eye diseases. As of now, the Group has obtained registration approvals for eight ophthalmic products, and our product pipeline is steadily expanding while our innovation capabilities continue to improve. We will remain committed to our corporate mission of “Creating Value, Serving Health,” and continue to focus on excellence in the ophthalmology field. We will rigorously control every stage of production and operations, continuously enhance product quality and service standards, and make positive contributions to the health of the people!